Ornisid 500 mg vaginal (5 tablets)

The instruction for medical use of ORNISID® medicine the Trade name of Ornisid® the International unlicensed name Ornidazol Lekarstvennaya the Tablet form vaginal 500 mg Structure One tablet contains active agent - ornidazol 500.00 mg excipients: calcium hydrophosphate, lactoses monohydrate, anhydrous citric acid, K 30 polyvinylpirrolidone, magnesium stearate, starch prezhelatinizirovanny, starch corn, avitsell rn 102. Description of the Tablet, white or almost white, pear-shaped form, slightly convex on both sides. Pharmacotherapeutic group Drugs for treatment of an amebiasis and other protozoan infections. Nitroimidazole derivatives. Ornidazol the ATX G01AF06 Code the Pharmacological Pharmacokinetics Researches properties of pharmacokinetics of drug were not conducted in connection with low system adsorption. The pharmacodynamics of Ornisid® possesses antibacterial and antiprotozoan action. Interacting with DNA of a microbic cell, causes disturbance of its helical structure, a rupture of threads, suppresses synthesis of nucleic acids and causes death of microbic cells and cells of protozoa. Орнисид® (ornidazol) it is active concerning protozoa: Trichomonas vaginalis, Entamoeba histolitica, Gardnerella vaginalis. Giardia intestinalis, Lambilia. And also concerning anaerobic cocci: Peptostrepococcus, Peptococcus. Indications - trichomoniasis at women: a mecotic vulvovaginitis, an urethritis, a bartholinitis, a cervicitis, an adnexitis, etc. - a bacterial vaginosis - the bacterial vaginita caused by banal piogenic flora - prevention of infections after surgical and gynecologic interventions: before gynecologic operations, before childbirth or abortion, before installation of Naval Forces, before and after diathermocoagulation of a neck of the uterus, before a gisterografiya the Route of administration and doses Is recommended use of a combination vaginal and peroral dosed For treatment of trichomoniasis: A route of administration the Single dose of 1.0 g (2 oral tablets on 500 mg) inside + 1 vaginal tablet before going to bed 5 day treatment of 500 mg (1 oral tablet) in the morning, in the evening + 1 vaginal tablet before going to bed Before going to bed the vaginal tablet Ornisid® to enter 500 mg (1 oral tablet) into a vagina, having previously carefully washed up hands. After introduction it is necessary to lie down 10-15 minutes. Side effects - burning sensation, local irritation (at the beginning of therapy) - allergic reactions. Contraindications - hypersensitivity to drug components - organic central nervous system diseases - the I trimester of pregnancy and the period of a lactation Medicinal interactions At combined use of Ornisida® with other derivatives of the 5th nitroimidazole can be observed a peripheral neuropathy, a depression and epileptiform spasms. Ornidazol does not inhibit an aldegiddegidrogenaza and therefore does not interact with alcohol. Simultaneous use with inductors of microsomal enzymes (barbiturates, benzodiazepines, rifampitsina, etc.) reduces a half-life period of an ornidazol in serum. Inhibitors of microsomal enzymes (Cimetidinum, macroleads, etc.) increase a half-life period of an ornidazol. Ornidazol strengthens action of anticoagulative means that demands correction of their dose. The combination of an ornisid with neurotoxic and gematotoksichny drugs is not recommended. Special instructions In trichomoniasis it is necessary to carry out simultaneous treatment of the sexual partner in order to avoid repeated infection. Pregnancy Use of drug in 2 and 3 trimesters is possible only when the expected advantage for mother and the child exceeds potential risk for a fruit. Oral use of vaginal tablets is not allowed! The overdose Due to low extent of absorption in a system blood stream overdose is improbable. A form of release and packing On 3 or 5 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil. On 1 blister strip packaging together with the instruction for use in the state and Russian languages place in a folding cardboard pack. To Store storage conditions in the dry, protected from light place, at a temperature not over 30 ºС. To store out of children's reach! 3 years not to apply a period of storage after the expiration date specified on packing. Prescription status According to the prescription ABDI IBRAHIM Istanbul Producer, Turkey the Owner of the registration certificate of ABDI IBRAHIM Istanbul, Turkey the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products and responsible for post-registration observation of safety of medicine in the territory of the Republic of Kazakhstan Abdi Ibrahim Global Pharm LLP, the Republic of Kazakhstan